| Identification | Back Directory | [Name]
[3-(4-methylphenyl)-5-[(E)-morpholin-4-ylmethylideneamino]imidazol-4-yl]-phenylmethanone | [CAS]
385425-03-6 | [Synonyms]
IBS008738
[3-(4-methylphenyl)-5-[(E)-morpholin-4-ylmethylideneamino]imidazol-4-yl]-phenylmethanone
Methanone, [1-(4-methylphenyl)-4-[(4-morpholinylmethylene)amino]-1H-imidazol-5-yl]phenyl- | [Molecular Formula]
C22H22N4O2 | [MDL Number]
MFCD01551710 | [MOL File]
385425-03-6.mol | [Molecular Weight]
374.44 |
| Chemical Properties | Back Directory | [Boiling point ]
618.3±65.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (133.53 mM; Need ultrasonic) | [form ]
Solid | [pka]
3.47±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model[1][2]. | [Biological Activity]
Cell permeable: yes''Reversible: yes | [in vivo]
IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles[1].
IBS008738 (30 μM, 100 μL) prevents Dexamethasone (HY-14648)-induced muscle atrophy[1].
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI)[2]. | Animal Model: | Six-week-old female BALB/cByJ mice[1] | | Dosage: | 3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS) | | Administration: | Injected into the tibialis anterior (TA) muscle of mice under anesthesia. | | Result: | Facilitated muscle repair in Cardiotoxin-injected muscles. |
| Animal Model: | Six-week-old female BALB/cByJ mice[1] | | Dosage: | 30 μM (100 μL) | | Administration: | Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13. | | Result: | Prevented Dexamethasone-induced muscle atrophy. |
| [References]
[1] Yang Z, et al. Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol. 2014;34(9):1607-1621. DOI:10.1128/MCB.01346-13
[2] Zou R, et al. TAZ Activator Is Involved in IL-10-Mediated Muscle Responses in an Animal Model of Traumatic Brain Injury. Inflammation. 2017;40(1):100-105. DOI:10.1007/s10753-016-0457-5 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|